All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Selank and semax: what the actual research says about these peptides

Stevielea Abberton

TikTok creator

1.5K viewsWatch on TikTok→

Quick answer

The creator self-administered selank intranasally five times and semax once, reporting no clear subjective effect and attributing this either to product quality or individual non-response. Both compounds act on central nervous system pathways (selank on GABA-A and serotonin systems, semax on BDNF and dopaminergic signaling) with short elimination half-lives, meaning acute subjective effects, if present, would typically appear within 30 to 60 minutes of intranasal administration. Individual non-response is plausible and documented in the limited available literature, and absence of effect does not confirm or rule out product quality issues without independent third-party testing.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.

What did @stevieleaabberton actually say?

She tried selank five times and semax once, starting low and working up to what she described as 'a fairly large dose,' and her honest conclusion was: 'I feel like if you know, you know, and I'm just not.' She's publicly uncertain whether the issue is the supplier's product quality or her own physiology, and she's not naming the supplier until she can rule out a 'me problem.' That's actually a more careful position than most peptide content on TikTok takes.

She also mentions she's already placed a bulk order with her usual tested supplier, which suggests she's approaching this as a preliminary trial rather than a product endorsement. The confusion is genuine. She's not selling certainty here, and that's worth acknowledging before we get into what she got right and wrong.

Does the science back this up?

The idea that you should 'feel it immediately' with selank and semax has some basis in the literature, but it's more complicated than the biohacking community usually admits. Both peptides have short half-lives and central nervous system activity that can, in some studies, produce rapid anxiolytic or cognitive effects, but individual response variation is real and documented.

Selank is a synthetic analogue of tuftsin, a naturally occurring tetrapeptide. A 2008 study by Semenova et al. in the Bulletin of Experimental Biology and Medicine found anxiolytic effects in animal models at relatively low doses, but human data is thin and mostly from Russian clinical trials with methodological limitations. Semax, a synthetic ACTH fragment, has been studied for cognitive function and neuroprotection primarily in Russian research settings (Akhapkina and Akhapkin, 2013, Zhurnal Nevrologii i Psikhiatrii). Neither compound has completed large-scale Western randomised controlled trials. So when she says she doesn't feel a difference, that's entirely plausible, and not necessarily a quality problem.

What did they get wrong (or right)?

She gets credit for the supplier skepticism. Unregulated peptide markets have documented purity problems. A 2022 analysis published in JAMA Internal Medicine (Cohen et al.) found that a significant proportion of peptides purchased from research chemical suppliers did not match their labeled concentration. Her instinct to test before bulk-buying is sound consumer behavior in a poorly regulated space.

Where she's on shakier ground: the assumption that 'it should work straight away' is partly correct for some users but not a reliable diagnostic. Selank's anxiolytic profile may be subtle enough that people with low baseline anxiety don't register a noticeable shift. The fact that she 'feels calm' after her last dose is not nothing, but she may be expecting a subjective signal that doesn't match how these peptides actually work for people who aren't starting from a high-anxiety baseline. Also, the Easter show semax trial is genuinely confounded data, and she's right to flag that.

What should you actually know?

Selank and semax are not approved by the FDA or TGA for any therapeutic indication. They are not legal to prescribe or sell as medicines in most Western countries, and the research base supporting their use in humans is largely derived from Soviet-era and post-Soviet Russian literature, which carries real methodological concerns around blinding and reporting standards.

That doesn't mean they're inert. It means the dose-response relationship, individual variability, and safety profile in human populations are genuinely unknown by the standards of modern clinical evidence. If you're not feeling an effect, that could reflect poor product quality, your individual neurochemistry, an insufficient dose, or the real possibility that the effect size in healthy adults is smaller than anecdotal reports suggest. None of those possibilities can be ruled out from five intranasal administrations. Anyone considering these compounds should be doing so under medical supervision, not from a TikTok stack recommendation.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 4 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Selank and semax: what the actual research says about these peptides, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Selank and semax: what the actual research says about these peptides should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

Use the health tools and supporting evidence to prepare questions for your clinician.

Claim verdict

The useful answer behind this video

Claim being checked

The creator self-administered selank intranasally five times and semax once, reporting no clear subjective effect and attributing this either to product quality or individual non-response.

FormBlends verdict

The creator self-administered selank intranasally five times and semax once, reporting no clear subjective effect and attributing this either to product quality or individual non-response. Both compounds act on central nervous system pathways (selank on GABA-A and serotonin systems, semax on BDNF and dopaminergic signaling) with short elimination half-lives, meaning acute subjective effects, if present, would typically appear within 30 to 60 minutes of intranasal administration. Individual non-response is plausible and documented in the limited available literature, and absence of effect does not confirm or rule out product quality issues without independent third-party testing.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator self-administered selank intranasally five times and semax once, reporting no clear subjective effect and attributing this either to product quality or individual non-response. Both compounds act on central nervous system pathways (selank on GABA-A and serotonin systems, semax on BDNF and dopaminergic signaling) with short elimination half-lives, meaning acute subjective effects, if present, would typically appear within 30 to 60 minutes of intranasal administration. Individual non-response is plausible and documented in the limited available literature, and absence of effect does not confirm or rule out product quality issues without independent third-party testing.
  • Neither selank nor semax is approved by the FDA, TGA, or EMA for any medical indication, and both are classified as research chemicals in most Western jurisdictions.
  • The human clinical trial evidence for both compounds is almost entirely from Russian literature, much of it published before 2010, with limited blinding and small sample sizes that don't meet current RCT standards.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Neither selank nor semax is approved by the FDA, TGA, or EMA for any medical indication, and both are classified as research chemicals in most Western jurisdictions.
  • The human clinical trial evidence for both compounds is almost entirely from Russian literature, much of it published before 2010, with limited blinding and small sample sizes that don't meet current RCT standards.
  • A 2022 JAMA Internal Medicine analysis (Cohen et al.) found that research chemical suppliers frequently mislabel peptide concentrations, making third-party testing a legitimate and important step before use.
  • Selank's proposed mechanism involves modulation of GABA-A receptors and serotonin transporter activity, meaning its anxiolytic effect may be subtle or absent in people who do not have elevated baseline anxiety.
  • Semax is theorised to upregulate BDNF and modulate dopaminergic pathways, but cognitive enhancement effects in healthy adults without neurological deficits are not well supported by controlled human data.
  • Individual non-response to peptides is biologically plausible and not automatically a sign of poor product quality. Receptor expression, hormonal status, and baseline neurochemistry all influence response.
  • Anyone using these compounds without medical supervision is operating without safety monitoring. Adverse event data for intranasal selank and semax in humans is extremely limited in published literature.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Stevielea Abberton · TikTok creator

1.5K views on this video

Let me know., would I know? I’m so confused I’d love feedback #selank #semax #biohacking #research #forresearchpurposes

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Stevielea Abberton, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.